Our history
Canonpharma production has been taking care of human health for over 20 years through the use of cutting-edge pharmaceutical developments to treat an extensive range of diseases. Production of effective and safe medicines is our corporate fundamental “canon”.
The world’s population is over 7 billion people and each person is unique. What makes us different from each other is unique appearance, striking character traits, individual abilities and talents. But there is one thing which unites all people. It’s our values! Life and health are the great treasures for any person.
Helping people live healthier and more fulfilling lives!
Canonpharma production has modern, high-tech full-cycle production facilities that were designed, constructed and equipped in compliance with GMP requirements. We are constantly adding the latest state of the art equipment and expanding our product line by launching generic medicines as well as new preparations that are not present on the market.
Our product portfolio is based on morbidity patterns of our target markets, contemporary treatment trends, as well as basic therapeutic regimens used by experts of the leading scientific and healthcare.
We make modern medicines affordable to the people
We have an internal multi-level system of quality control that consists of incoming control of all raw materials and excipients, production process controls, quality control of ready-made preparations, sanitary control as well as technological process compliance control
Effectiveness and safety of our medicines are literally our “canon”, whilst one of our main goals is to establish a manufacturing base that would be in line with the highest international quality standards.
Canonpharma product portfolio today covers almost all therapeutic areas. Most of our preparations are included into the list of vital and essential medicines and the lists of preferential provision of medicines. Some of these medicines have no domestic analogues; moreover, they are also on the lists of medicines that have prioritized production status in the Russian Federation.
The Company portfolio comprises over 300 product names.
Our cardiologic “portfolio” comprises the most demanded medicines, such as Deprenorm® MV (delayed-release trimetadizine), CardiASK® (acetylsalicylic acid), Aritel® (bisoprolol), Aritel® Plus (bisoprolol and hydrochlorothiazide), Fosinap® (fosinopril), Angiakand (candesartan), Irsar® (ibersartan), Felotenz® (felodipine), Amlodipinum, Atorvastatin, etc., as well as Deprenorm® MV 70 mg, the first single-dose cytoprotector in Russia.
Deprenorm® MV 70 mg was awarded with “Socially significant medicine” prize at the II awards ceremony of the “Foresight of health” international project in 2013.
Our portfolio contains over 300 products
Products for treatment of neurologic diseases include Vinpotropile® (vinpocetine and piracetam), Thiolepta® (alpha-lipoic acid), Meksi B6® (ethylmethylhydroxypyridine succinate) and Betahistine.
Canonpharma products for treatment of gastroenterological diseases include Phosphonciale® (phospholipids and flavonoids of milk thistle), Sparex® (mebeverine), Exhol® (ursodeoxycholic acid), including the unique Exhol® 500 mg.
Our company is also actively developing a product line for diabetes care. Currently we have a separate portfolio of medicines for treatment of this disease. It includes such medicines as Glimepiride, Metglib®, Metformin, Fenofibrate, Gliclazide and others.
Another major objective of Canonpharma is development of original combination dosage forms, as well as finding ways to improve patient’s quality of life by offering medicines with improved properties. Some of such examples include preparations like Phosphonciale® from our gastroenterological portfolio, Deprenorm® in the cardiologic group and Vinpotropile® from the neurology segment.
We cooperate with the leading medical experts in our country, however it is equally important for us to cooperate with experts on all levels so that they could gain experience in the use of our products and form an opinion regarding their quality and properties. This helps our company to provide consumers with high-quality generic medicines at much more affordable prices and contributes to fulfillment of our mission.
In 2018 Sparex® became a winner of “PRIORITY-2018” National award in the field of import substitution.
Vinpotropile® was nominated for “PRIORITY-2018” National award in the field of import substitution.
Deprenorm® MV was nominated for “PRIORITY-2018” National award in the field of import substitution.